Simvastatin accelerated motoneurons death in SOD1\textsuperscript{G93A} mice through inhibiting Rab7-mediated maturation of late autophagic vacuoles

Lin Bai\textsuperscript{1,2}, Yafei Wang\textsuperscript{1,2}, Jia Huo\textsuperscript{1,2}, Shuai Li\textsuperscript{1,2}, Ya Wen\textsuperscript{1,2}, Qi Liu\textsuperscript{1,2}, Jing Yang\textsuperscript{1,2}, Yaling Liu\textsuperscript{1,2} and Rui Li\textsuperscript{1,2}

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease caused by motoneuron loss, for which there is currently no effective treatment. Statins, as inhibitors of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, are used as drugs for treatment for a variety of disease such as ischemic diseases, neurodegenerative diseases, cancer, and inflammation. However, our previous evidence has demonstrated that simvastatin leads to cytotoxicity in NSC34-hSOD1G93A cells by aggravating the impairment of autophagic flux, but the role of simvastatin in ALS model remains elusive. In present study, we reported that after simvastatin treatment, SOD1G93A mice showed early onset of the disease phenotype and shortened life span, with aggravated autophagic flux impairment and increased aggregation of SOD1 protein in spinal cord motoneurons (MNs) of SOD1\textsuperscript{G93A} mice. In addition, simvastatin repressed the ability of Rab7 localization on the membrane by inhibiting isoprenoid synthesis, leading to impaired late stage of autophagic flux rather than initiation. This study suggested that simvastatin significantly worsened impairment of late autophagic flux, resulting in massive MNs death in spinal cord and accelerated disease progression of SOD1\textsuperscript{G93A} mice. Together, these findings might imply a potential risk of clinic application of statins in ALS.

Introduction

Amyotrophic lateral sclerosis (ALS) is a rare progressive neurodegenerative disease characterized by the selective demise of motoneurons (MNs). Muscle weakness and atrophy are symptoms that ultimately lead to respiratory failure and death, usually within 3–5 years\textsuperscript{1}. Approximately 90% of ALS cases are sporadic (sALS), whereas the remaining 10% are familial (fALS). Moreover, ~20% of fALS and 5% of sALS cases are attributed to mutations in the Cu/Zn-superoxide dismutase (SOD1) gene\textsuperscript{2,3}. Although several possible pathogenic mechanisms, including protein aggregation, mitochondrial dysfunction, impaired RNA processing and metabolism, neurotrophic factor deficiency, and axoplasmic transport abnormality\textsuperscript{4–6} are currently reported, the potential causes of ALS remains poorly understood.

Macroautophagy (hereafter autophagy) is an important lysosomal degradation route in which cytosolic components, especially long-lived or misfolded/aggregate-prone proteins, damaged whole organelles, are effectively removed and recycled\textsuperscript{7}. Autophagy involves the sequestration of cytoplasmic materials into a double-membrane autophagosomes (APs) and subsequent delivery to lysosomes for catabolism\textsuperscript{8}. In fact, nascent APs are capable of trafficking to the lysosome and fusing with early or late phase endosomes/lysosomes and subsequent forming degradative autolysosomes, a process known as AP maturation\textsuperscript{8}. The small GTP binding protein Rab7 is a member of the Rab family that has been required for late endosomal/autophagosomal transport and finally participated in the fusion step with lysosomes\textsuperscript{9–11}. Neurons appear to be particularly dependent on autophagy\textsuperscript{12}.
Aberrant autophagy including hyperactive autophagy induction, defective AP formation, or dysfunction of AP maturation could result in protein aggregation and finally neuronal death. Abnormal autophagy has been found in several neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), as well as ALS.\textsuperscript{3,13–15}

The mevalonate (MVA) pathway is essential for sterols synthesis, especially cholesterol and also plays a key role in producing isoprenoids, such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), which are necessary sources for protein prenylation. In particular, prenylation comprises an important posttranslational process that modifies a variety of proteins, such as the family of small GTPase proteins (Rabs and Ras family), and ensures their correct localization on membranes.\textsuperscript{16} MVA pathway affects various metabolism pathways, such as protein synthesis and degradation, intracellular signaling, cell growth, and differentiation or death.\textsuperscript{17–19} Furthermore, several studies reported that severe reduction of protein prenylation by MVA pathway blockade has been linked to defective autophagy.\textsuperscript{17,20}

Statins act as inhibitors of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (HMGCR), a rate-limiting enzyme in the MVA pathway, which catalytically converts HMG-CoA into MVA. By lowering LDL levels, statins have been widely used in the clinic for treating hypercholesterolemia, cardiovascular, and cerebrovascular disease.\textsuperscript{21–23} Moreover, the pleiotropic effects (independent cholesterol) of statins have a protective effect in many diseases, including AD, PD, and multiple sclerosis (MS).\textsuperscript{24–26} However, accumulating data have suggested that statins increased risk of diabetes, liver disorders, or myopathy\textsuperscript{27–29}. Thus, the role of statins remains controversial. Some patients with ALS exhibited the symptoms of cardiovascular and cerebrovascular disease, and it remains unclear whether statin treatment is detrimental for ALS.

We have shown previously that simvastatin increased cytotoxic effects on NSC34-hSOD1\textsuperscript{G93A} cells, which could be attributed to the impaired impairment of autophagic flux by reducing synthesis of isoprenoids rather than cholesterol.\textsuperscript{30} Therefore, to further clarify the detailed effect of statin in vivo, we used ALS mice model through specific mutation of SOD1. Here, we showed that statins inhibited activity of Rab7 via reduction of FPP and GGPP in the MVA pathway, which in turn further aggravated defect of late autophagic flux and finally led to massive neuronal death in SOD1\textsuperscript{G93A} mice.

**Materials and methods**

**Chemicals**

Simvastatin (Cat. No: S6196), FPP (Cat. No: F6892), GGPP (Cat. No: G6025), and CID1067700 (SML0545) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Sodium carboxymethyl cellulose (CMC-Na, Cat. No: C8621). FPP and GGPP are liquid format. Simvastatin was dissolved in CMC-Na. CID1067700 was dissolved in dimethyl sulfoxide (DMSO).

**Animals and treatments**

Transgenic SOD1\textsuperscript{G93A} mice (B6SJL-Tg [SOD1G93A] 1Gur/J) were originally obtained from Jackson Laboratory (Bar Harbor, ME, USA). The mice were maintained as hemizygotes by crossing transgenic males with wild type (WT) B6SJL/F1 females. Hemizygous mice were genotyped by PCR according to our previous protocol.\textsuperscript{31} The mice were housed in controlled temperature and humidity facility (light/dark cycle 12/12 h), while were fed sterile water and sterilized specific pathogen-free rodent food at will. Our preliminary study demonstrated that female SOD1\textsuperscript{G93A} mice showed more significant behavioral changes after administration of 20 mg/kg simvastatin, thus determining the gender of mice and the dosage of simvastatin (20 mg/kg). Simvastatin dissolved in 5% CMC-Na vehicle, then given by oral gavage once a day for mice. The SOD1\textsuperscript{G93A} mice have no symptoms or obvious pathological changes in spinal cord at 60 days. Thus, simvastatin treatment was started from 63 days (9th week) to the endstage. No obvious side effects were observed during the course of treatment. Female SOD1\textsuperscript{G93A} mice were randomized into two groups: Simvastatin group (G93A-Sim); Vehicle group (G93A-Con). Simultaneously, female-matched WT littermates were divided into WT-Sim and WT-Con groups. Each group of 18 mice was used to assess disease onset and life span. Additionally, the other SOD1\textsuperscript{G93A} mice and WT littermates were also treated from 63 days and sacrificed at 120 days of age. After treatments, the rest of the mice were subjected to histological analysis or Western blot analysis (five mice per group) as described below. Other mice were used for time point analysis (90 days, endstage; five mice per group). All animal experiments were conducted according to the management regulations of laboratory animal promulgated by the Second Hospital of Hebei Medical University. All experiments were approved by the Research Ethics Committee of the Second Hospital of Hebei Medical University (Shijiazhuang, Hebei, P.R. China, Approval No. 2020P023).

**Assessment of disease onset and life span**

In order to assess the motor functions of mice, we performed three clinical tests: (i) weighed, (ii) performed the rotarod test, and (iii) scored of neurological deficits. All of these tests are usually used to evaluate SOD1\textsuperscript{G93A} mice.\textsuperscript{32} Body weight was measured once per week, starting at 63 days (9th week) of age. Assessed the disease onset of
SOD1<sup>G93A</sup> mice by rotarod test. After 5-day training session, the rotarod test was performed at a constant speed (Rotarod test apparatus: 4 cm diameter, 20 rpm). The tests started from 9th week for once a week, then from 12th week for twice a week. All mice were measured three times (5 min/trial), 10-min interval for each test. When the mice could not insist 5 min for the longest run time at all three trials that will be recorded to the disease onset. Scored of neurological deficit as following four-point scoring system<sup>33</sup>. Score of 4: normal (no sign of motor dysfunction); Score of 3: hind limb tremors are evident when suspended by the tail; Score of 2: gait abnormalities are present; Score of 1: drag of at least one hind limb; Score of 0: inability to right itself within 30 s. For the lifespan, the inability of SOD1<sup>G93A</sup> mice to right themselves within 30 s of being place on their back was defined as the date of “end stage”.

**Histology**

Mice were deeply anesthetized by chloral hydrate and transcardially perfused by phosphate buffered saline (PBS, PH7.4) and followed by ice-cold 4% paraformaldehyde (PFA) in PBS. Spinal cords were harvested then postfixed in 4% PFA overnight, and then equilibrated in 10 and 30% sucrose/PBS at 4 °C for 24 h, respectively. Lumbar spinal cords were embedded in O.C. T. medium, then consecutive cut in 8 μm transverse sections by cryostat microtome. For MNs counting, sections were stained with 1% cresyl violet using a standard protocol, dehydrated in gradient alcohol, and cleared in xylol. Nissl-positive MNs were counted from ventral horns per mouse (five mice per group), which considered as neuronal morphology, diameter exceeding 8 μm and a distinct nucleolar profile. We observed the sample slides, photographed by microscope (Olympus, BX51, Tokyo, Japan) and counted MNs in the ventral horns of both sides. The MNs were counted by independent investigator who was blinded to groups.

**Immunofluorescence Staining**

The lumbar spinal cords (L4-L5) at 120 days of age were obtained for immunofluorescent staining. Lumbar spinal cords were dissected and cut into 20 μm transverse sections. The frozen sections were placed for 20 min at room temperature, and then washed with PBS for three times (5 min/time). Tissue sections were blocked in 10% goat or donkey serum in PBS-0.3% Triton X-100 for 1 h at room temperature and incubated with primary antibodies against CHAT antibody (1:1000, Abcam, ab178850), NeuN (1:500, CST, #24307 s), GFAP (1:500, CST, #3670 s), Iba1 (1:500, Abcam, ab178847), LC3 (1:200, Santa, sc-376404), P62 (1:500, Sigma, P0067), LAMP2 (1:200, Abcam, ab25631), LC3 (1:500, Sigma, L7543), SOD1 (1:200, Abcam, ab16831), or Rab7 (1:200, Abcam, ab137029) overnight at 4 °C. Then sections were washed in PBS for three times and incubated with Alexa Fluor 488-conjugated Goat anti-Rabbit secondary antibody (1:1000, Thermo Fisher, #A-11034), Alexa Fluor 594-conjugated Goat anti-Mouse secondary antibody (1:1000, Thermo Fisher, #A-11032), or Alexa Fluor 647-conjugated Donkey anti-Goat secondary antibody (1:1000, Thermo Fisher, #A211447) for 1 h at room temperature. After washing (PBS, three times), nuclei were counter stained with DAPI Fluoromount-G (Southern Biotech). The sections were visualized with a fluorescence confocal microscope (Olympus FV1000). The parameters of experimental setup are determined at the beginning of each individual imaging process and remain constant throughout the imaging process. The mean number, including LC3 or Rab7 puncta/cell, colocation of P62/LC3 or LC3/LAMP2, NeuN/Rab7, GFAP/Rab7, Iba1/Rab7 and CHAT was counted by an investigator blinded to groups. The mean fluorescence density of P62, SOD1, GFAP, or Iba1 was analyzed with ImageJ. The above experiments were repeated three times with five mice in each group.

**Western blotting**

Proteins were extracted using a bicinechoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, 23225, Waltham, MA, USA). Equal amount of proteins (40 μg) were separated by 10 or 12% SDS-PAGE and then transferred to PVDF membranes. After blocking by 5% nonfat milk, the membranes were incubated with primary antibodies overnight at 4 °C, and then washed three times (10 min/time), subsequently with secondary antibodies for 1 h at room temperature. Finally, the bands on the membranes were scanned with an Odyssey Infrared Imaging System (LI-COR, Lincoln, NE, USA), and quantitation analysis was performed with ImageJ.

The primary antibodies: P62 (1:1000, Sigma, P0067), LC3 (1:1000, Sigma, L7543), SOD1 (1:200, Abcam, ab16831), HMGCR (1:200, Santa, sc-271595), FDPS (1:100, Proteintech, 16129-1), RABGGTA (1:100, Proteintech, 14448-1), Rab7 (1:500, Abcam, ab137029), and β-actin (1:1000, Proteintech, 60008-1).

**Electron microscopy**

Mice were deeply anesthetized and follow perfused with 4% PFA and 2.5% glutaraldehyde in PBS. The spinal cord was dissected and postfixed in 4% glutaraldehyde at 4 °C for 24 h. After the tissues were washed three times, they were postfixed with 1% osmium tetroxide for 2 h, and then stained with 1% uranyl acetate for 1 h. Next, the tissues were embedded in epoxy resin after being dehydrated by gradient ethanol. Ultra-thin sections (70 nm thick) were prepared for electron microscopy analysis. The ultra-thin sections were observed and imaged under a transmission electron microscopy (TEM, JEM-1230). Five mice were
used at each group, taken the lumbar spinal cords for thin sections from each mouse. Five sections were cut per tissue. Ten electron micrographs taken from the neurons of the anterior crus of lumbar spinal cord were taken per section. Morphometrical measurements of APs were carried out using the point-counting method. The number of APs in the cytoplasm of MNs in WT and SOD1G93A mice groups were counted by an investigator blinded to groups and compared.

**NSC34 cell culture and transfection**

Mouse neuroblastoma x spinal cord (NSC34) cells retain the ability of proliferation and exhibit the characteristics of MNs. NSC34 MN-like cells stably expressing GFP-empty vector (E), GFP-human SOD1 wild type (hSOD1WT), or GFP-human SOD1G93A (hSOD1G93A) constructs were generated as previously described in our laboratory. For all experiments, the cells were starved in serum-free Dulbecco's modified Eagle's medium (DMEM) for 24 h, and then incubated in medium containing simvastatin (1 µM) alone or coculture FPP (10 µM) or GGPP (10 µM) for 24 h. For the CIDI067700 (CID) experiments, NSC34-E and NSC34-hSOD1G93A cells were treated with CID (40 µM) for 2 h, or NSC34-hSOD1G93A cells were incubated with GGPP (10 µM) for 24 h and CID (40 µM) was added to the cells in the last 2 h before harvesting.

**Cell lysis and immunoblotting**

Cells were lysed in IP buffer containing phenylmethylsulfonylfluoride (PMSF), and protease inhibitors for 30 min on ice. The cell lysates were centrifuged at 10,000 rpm for 10 min at 4 °C to collect supernatants. Protein concentrations were measured with BCA protein assay kit. Proteins were electrophoresed and transferred to PVDF membranes and incubated with antibody. Finally, the bands were quantified using ImageJ software. The following primary antibodies: P62 (1:500, Sigma, P0067), LC3 (1:1000, Sigma, L7543), SOD1 (1:2000, Abcam, ab25631), LC3 (1:500, Sigma, L7543), SOD1 (1:400, Abcam, ab16831), or Rab7 (1:500, Abcam, ab137029) overnight at 4 °C. The cells were washed with PBS for three times and stained with secondary antibodies, Alexa Fluor 594-conjugated goat anti-rabbit (1:1000, Thermo Fisher, #A-11037) or Alexa Fluor 647-conjugated goat anti-mouse (1:1000, Thermo Fisher; #A-21236), for 1 h at room temperature, then stained nuclei with DAPI Fluoromount-G (Southern Biotech). Finally, imaged the cells by confocal microscopy.

**Filipin staining**

Cells were processed as described. After 4% PFA post-fixed and PBS rinsed, cells were incubated with 1 ml glidine (1.5 mg/ml PBS) for 10 min. Then, cells were stained with 0.3 mg/ml Filipin (Sigma, SAE0088) in PBS (working solution) for 2 h at room temperature. Intracellular free cholesterol was stained by Filipin and fluoresced blue (excitation of 340–380 nm and emission of 385–470 nm).

**Statistical methods and analyses**

Data were obtained from three independent experiments. The comparisons of disease onset and life span among groups were statistically analyzed by Kaplan–Meier survival analysis. Unpaired t-test was used to examine significant differences between two groups. Other statistical significances were evaluated by one-way ANOVA test to obtain multiplicity adjusted p values. Significance being defined as *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001; †P ≤ 0.05, ††P ≤ 0.01, †††P ≤ 0.001. Statistical analysis was performed by GraphPad software. Data were expressed as the mean ± SEM.

**Results**

Simvastatin aggravated impairment of autophagic flux in SOD1G93A mice

We firstly detected the levels of P62 and LC3, the classic markers to evaluate ability of autophagic flux, in the lumbar spinal cords of SOD1G93A mice at 120 days. We found that P62 and LC3 are expressed at higher level in SOD1G93A mice than those in WT mice, which was consistent with previous studies. Importantly, in mice treated with simvastatin (G93A-Sim group), both of P62 and LC3 expression were increased significantly compared with control (G93A-Con group), but there is no significant difference between WT-Con and WT-Sim groups.
In addition, lots of P62 immunoreactive puncta were detectable in the lumbar spinal cords of SOD1G93A mice, and these aggregates were extremely increased by long-term simvastatin treatment (Fig. 1B). Notably, expression of LC3 was enhanced in the NeuN-positive MNs of G93A-Con compared with WT, and G93A-Sim group displayed higher LC3 aggregation. However, no significant difference was observed between WT-Con and

---

**Fig. 1** Simvastatin aggravated impairment of autophagic flux in SOD1G93A mice. **A** Western blot analysis of P62 and LC3 in the lumbar spinal cords of WT and SOD1G93A mice treated with or without simvastatin at 120 days. Quantification of P62 and LC3 levels from immunoblots normalized to the WT-Con group. **B** Immunofluorescence labeling of P62 (green) in the lumbar spinal cord at 120 days (Scale bar, 100 μm). Quantification of the average density of P62-positive cells per section. **C** Immunofluorescence labeling of LC3 (red) in NeuN-positive motoneurons (green) at 120 days (Scale bars, 10 μm). Quantitative analysis of LC3 puncta. **D** TEM micrographs showed that APs are present in the cytoplasm of MNs in SOD1G93A mice at 120 days and that these structures are absent or rare in MNs of WT mice (red arrowheads; N, nucleus; scale bar, 1 μm). The upper right image shows magnifications for the red dotted box, as shown in the red solid line box. The histogram shows the quantification of APs per cell. (Data represent the mean ± SEM, n = 5 mice per group; statistical significance was assessed by one-way ANOVA or an unpaired t-test, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, "P ≤ 0.05, ""P ≤ 0.01, """"P ≤ 0.001).
WT-Sim groups (Fig. 1C). Moreover, a large number of closed double-membrane-bound APs were observed by TEM analysis in the cytoplasm of MNs in G93A-Con mice, and the number of APs were remarkably upregulated after treated with simvastatin (Fig. 1D, as shown by arrowheads). These results suggested that simvastatin was able to further aggravate the disruption of autophagic flux in SOD1<sup>G93A</sup> mice, and this effect might be linked to early enhanced autophagy induction or defective degradation at the late stage.

**Simvastatin increased the aggregation of the SOD1 protein in the lumbar spinal cords of SOD1<sup>G93A</sup> mice**

Misfolding and aggregation of mutant SOD1 (mSOD1) is a pathological hallmark of a subset of FALS patients and is involved in pathogenesis<sup>3,39,40</sup>. As expected, compared with WT group, increased expression of SOD1 protein was detectable in the lumbar spinal cords of G93A-Con mice at 120 days, and was drastically elevated after simvastatin administration (Fig. 2A). Consistent with the western blot data, amount of SOD1 aggregation were significantly upregulated in SOD1<sup>G93A</sup> mice treated with simvastatin by immunostaining (Fig. 2B). We further found the higher abundance of autophagic vacuoles labeled with SOD1 colocalized with P62, the ubiquitin-binding domain-containing receptor in G93A-Sim mice compared with G93A-Con (Fig. 2C). Next, we compared protein levels of P62, LC3, and SOD1 in the lumbar spinal cords of SOD1<sup>G93A</sup> mice treated or untreated with simvastatin over the course of disease progression. All of the expression of the P62, LC3, and SOD1 proteins in the G93A-Sim group showed dramatic increase from 120 days to the end stage compared to G93A-Con (Fig. 2D). These results indicated that simvastatin extensively enhanced the level of SOD1 aggregation in G93A-Con mice associated with increased defect of autophagic flux.

**Simvastatin blocked the late stage of autophagic flux rather than early initiation**

To determine at what stage dose the blockage of autophagic flux occur, we firstly double labeled p62-LC3. Autophagy substrates (p62/SQSTM1) directly binds to the AP membrane protein LC3 and is selectively degraded by autophagy, whereas LC3 and associating p62/SQSTM1 which localized on both outer and inner membranes<sup>3,45–47</sup>. To evaluate the fusion of P62 with LC3, a marker of AP formation, we quantified the percent of P62- and LC3-double positive structures and found no significant difference between the lumbar spinal MNs of G93A-Con and G93A-Sim at 120 days (Fig. 4A, arrowheads). To gain insight into the ability of AP maturation, double labeling of LC3 and LAMP2, an important lysosomal marker, was used to investigate fusion event between APs and lysosomes<sup>47</sup>. Compared with G93A-Con group, the percentage of colocalization of LC3 and LAMP2 was mainly reduced in MNs of G93A-Sim group (Fig. 4B, arrowheads). In agreement with these results, immunofluorescence staining in vitro also showed a significant reduction in the structure of LAMP2- and LC3- double positive in NSC34-hSOD1<sup>G93A</sup> cells after simvastatin treatment (Fig. 8B and S1B), but no significant effect on the colocalization of P62 and LC3 (Fig. 8A and S1A). Together, these results implied
that simvastatin could block the process of APs fusion with lysosomes in MNs of SOD1<sup>G93A</sup> mice.

**Simvastatin repressed recruitment of Rab7 to membranes in MNs of SOD1<sup>G93A</sup>**

Fusion events between APs and lysosomes play a key role in maintaining of autophagy flux balance. It is generally considered that Rab7 has functions in the maturation of late autophagic vacuoles<sup>48,49</sup>. Firstly, we investigated Rab7 localization to membrane via immunofluorescence, and the amount of Rab7-positive structures was ~50% less after simvastatin administration compared with SOD<sup>G93A</sup> mice, but there was no significant difference between WT-Con and WT-Sim groups (Fig. 5A, B). Paradoxically, western blot
Fig. 3 (See legend on next page.)
analysis indicated that the level of total Rab7 protein in cell was increased in both G93A-Con and G93A-Sim mice. We also noted a slight upregulation of Rab7 in the latter, but no significant statistical difference in the indicated two groups (Fig. 5C, D). To explain these results, we double stained for Rab7 and GFAP or Iba1. Compared to WT, increased colocalization of Rab7 and GFAP or Iba1 was seen in SOD1<sup>G93A</sup> mice, especially after simvastatin treatment (Fig. 5E). Meanwhile, Rab7 constructs were mainly visible in NeuN-positive cells of WT mice (Fig. 5A).
To understand the phenomenon of Rab7-positive structures, we also validated the localization of Rab7 to membranes in vitro. Quantitative analysis of western blot suggested that the level of total Rab7 protein was not significantly different among the groups (Fig. 6A, top row, 6C). Active Rab7 peripherally binds to membranes via protein...
prenylation. We next detected the abundance of Rab7 in membrane and cytosolic fractions by western blot. The results revealed that the fraction of membrane-associated Rab7 was extensively reduced in the NSC34-hSOD1-G93A cells treated with simvastatin while the fraction of Rab7 in the cytoplasm was distinctly elevated, but unaltered in NSC34-E cells (Fig. 6A, below row, 6C). Moreover, compared with NSC34-hSOD1-G93A, Rab7-localized structures were approximately invisible throughout the total body of simvastatin-treated NSC34-hSOD1-G93A cells, but there was no significant alteration in NSC34-E with or without simvastatin (Fig. 6B, D). Based on these results demonstrated that simvastatin repressed formation of membrane-associated Rab7 in MNs of SOD1-G93A.

The effect of isoprenoids on small GTPase protein Rab7 trafficking to membranes have been studied extensively in the past. Next, to investigate the role of statins on key enzymes closely involved in FPP and GGPP synthesis in MVA pathway (Fig. 7A), we performed western blot analysis. Our data represented that all of HMGCR, FDPS, and RABGGTA that respectively catalyzed production of MVA, FPP, and GGPP were obviously decreased in the lumbar spinal cords of G93A-Sim mice compared with G93A-Con at 120 days (Fig. 7B, D). Similar results were found in NSC34-hSOD1-G93A cells (Fig. 7C, E). However, simvastatin only moderately reduced the level of HMGCR in both WT mice and NSC34-E cells and unaffected the expressions of FDPS and RABGGTA (Fig. 7B–E). Taken together, these data displayed the inhibitory effect of

---

**Fig. 6 Simvastatin inhibited Rab7 localization to membranes in NSC34-hSOD1-G93A cells.** A The expression of Rab7 protein in total cell, membranes, cytosol for each group by western blot analysis. NSC34-E and NSC34-hSOD1-G93A cells were incubated with Simvastatin (1 µM) for 24 h. B Rab7-positive structures (red) in NSC34-E and NSC34-hSOD1-G93A cells treated or untreated with simvastatin (1 µM) for 24 h. Nuclei were stained with DAPI (blue, Scale bars, 5 µm). C Quantification of Rab7 protein in total cell, membranes, cytosol for each group. D Quantitative analysis of intracellular Rab7 puncta in each group. (Data represent the mean ± SEM, n = 20 cells per group; statistical significance was assessed by one-way ANOVA or an unpaired t-test, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ⋆P ≤ 0.05, †P ≤ 0.01, ‡P ≤ 0.001).
FPP or GGPP rescued defect of late autophagic flux and ameliorated aggregation of the SOD1 protein in NSC34-hSOD1G93A cells treated with simvastatin

To further explore the possibility of autophagy balance maintained by sufficient isoprenoids, FPP or GGPP was added to simvastatin-treated NSC34-hSOD1G93A cells. As shown in Fig. 8, FPP and GGPP decreased comparably accumulation of p62 and LC3 but their colocalisation (seen as yellow dots in the merge column) could not be affected (Figs. 8A and S1A). Consistent with Fig. 4, at the presence of simvastatin, colocalisation of LC3 and LAMP2 (yellow puncta) were drastically impeded leading to massive accumulation of LC3 and P62 in NSC34-hSOD1G93A cells and finally aggravated impairment of late autophagic flux (Figs. 8A, B and S1A, B). As we expect, colocalisation of LC3-positive APs to lysosomes marked by LAMP2-positive was significantly upregulated by simultaneous treatment of cells with simvastatin and
FPP or GGPP. Thus, these events improved blockage of autophagic flux and eliminated aggregation of SOD1 in NSC34-hSOD1<sup>G93A</sup> cells (Figs. 8A, B, C and S1A, B, D, E). Moreover, the inhibitory effect on activation of Rab7 was reversed by simvastatin combination with FPP or GGPP, which promoted relocation of active Rab7 to lysosomal membrane (Fig. 8D and S1C). Therefore, these results showed that inhibition of Rab7 activation
caused by reduced isoprenoid, including FPP or GGPP, led to enhanced simvastatin-induced defect of late autophagic flux.

Simvastatin worsened the disruption of APs fusion with lysosomes in NSC34-hSOD1G93A cell via reduced prenylation of Rab7

To further understand the role of Rab7 on coordinating fusion between APs and lysosomes in NSC34-hSOD1G93A cells after simvastatin incubation, we used CID1067700 (CID) to inhibit activity of Rab7. CID is a high-affinity and specific Rab7 inhibitor, which blocks the fusion of APs and lysosomes52,53. We thus investigated appearance of APs and Rab7 under CID administration both in NSC34-E (Fig. S2A) and NSC34-hSOD1G93A cells (Fig. 9). Upon simvastatin treatment, colocalization of Rab7- and LAMP2- positive constructs was almost completely abolished. In line with Fig. 8, supplementation of GGPP had a great effect on shift of active Rab7 and LC3-positive APs to lysosomes (yellow puncta, Figs. 9A, C and S2B, C), after which accumulation of P62 and LC3 started to decrease (Fig. 9B). Importantly, we found that GGPP combination with CID treatment changed Rab7 behavior and blocked the fusion and degradation of LC3-positive APs with lysosomes, which was similar to the phenotype induced by simvastatin treatment alone (Figs. 9A, C and S2B, C). Consistently, inhibition of Rab7 led to re-accumulation of P62 and LC3 (Fig. 9B). However, under either condition colocalization of LC3 and P62 was not altered in line with Figs. 4 and 8. In addition, we detected level of cholesterol by Filipin staining. The results showed that simvastatin had no effect on the intracellular free cholesterol in both NSC34-E and NSC34-hSOD1G93A cells even though NSC34-hSOD1G93A cells have lower free cholesterol than NSC34-E cells, which could be determined by the phenotype of the NSC34-hSOD1G93A cells (Fig. S1F). These experiments strengthened the notion that simvastatin functioned to suppress fusion of APs and lysosomes in NSC34-hSOD1G93A cells mainly by interfering with Rab7 prenylation.

Discussion

The MVA pathway, fundamental for cholesterol synthesis as well as production of non-sterols termed isoprenoids such as FPP and GGPP, is necessary for various metabolic pathways19,54. MVA pathway blockage has been associated to autophagy deficiency, possibly leading to cell death. The inhibitory function of statins on HMG-CoA reductase resulted in depletion of cholesterol and isoprenoids in MVA pathway19,55. Statins thus have therapeutic application in diseases like inflammatory disease, cancer, and neurodegenerative disease including AD, PD, and MS, probably due to its pleiotropic effects independent of lowering cholesterol levels24–26,56. However, impacts of statins on ALS have gained less attention. In present study, upon simvastatin treatment we evaluated autophagic performance in SOD1G93A mice that had been considered as a classic ALS model57. Expectedly, our date showed that simvastatin worsened defective autophagic flux causing increased accumulation of APs in SOD1G93A mice (Fig. 1). Additionally, we found that massive loss of MNs resulted in deterioration of disease progression, which could be highly linked to cytotoxicity effect of abnormal SOD1 aggregation mediated by deficient autophagy (Figs. 2 and 3). An important pathological feature of patients with ALS is that a large number of malformed proteins gathered in MNs leading to neuronal degeneration and death40,42,43. Thus, it is possible that simvastatin used in clinical practice in ALS may play a negative role.

Autophagy can be envisaged as a process to consist of autophagosomal formation, targeted transport, and fusion with lysosome that degraded cytosolic components engulfed in autophagic membranes7,8. AP formation is facilitated by p62 interacting LC3 to encase pathogens in APs8. Our results demonstrated that the ability of p62 binding to LC3 was not changed by simvastatin treatment (Fig. 4). We speculated that simvastatin had no impact on APs formation in the lumbar spinal cords MNs of SOD1G93A mice. Interestingly, reduced colocalization of LC3 and LAMP2 could reflect impaired fusion of APs with lysosomes, which may explain why simvastatin worsened defects of autophagic flux (Fig. 4).

It has been shown recently that prenylation of Rab small GTPases appears to be one of important mechanisms involved in autophagy regulation19. Among these, location of prenylated Rab7 to membrane is responsible for AP maturation and facilitating AP fusion to lysosome9–11. Here, we noted that simvastatin severely decreased Rab7 localization to the membrane in MNs of SOD1G93A both in vivo and in vitro. In contrast to the activity of Rab7-binding membrane in WT mice and NSC34-E cells unaffected (Figs. 5 and 6). This may suggest that MNs of SOD1G93A are more susceptible to be damaged by simvastatin. Additionally, we also found that Rab7 were mainly located in Iba1- and GFAP-positive cells in SOD1G93A mice, especially after simvastatin treatment. This may provide a sound explanation for upregulation of total Rab7 protein in the lumbar spinal cords of SOD1G93A mice with or without simvastatin whereas in vitro experiments do not (Figs. 5 and 6). However, the role of Rab7 in astrogliosis and microgliosis in spinal cord of SOD1G93A mice remains unknown.

Isoprenoids have been shown to be essential for protein prenylation, which are required for proper function of membrane-localized Rab and for normal autophagy19,58. In our previous work it has been shown that simvastatin aggravated autophagic disruption through reduction of...
isoprenoids in NSC34-hSOD1<sup>G93A</sup> cells<sup>30</sup>. In present study, we further saw that simvastatin extensively decreased the fraction of Rab7 associated with the membrane while increased the fraction of Rab7 in the cytoplasm, but unaltered in NSC34-E cells (Fig. 6). Statin has been shown to inhibit MVA pathway. We found that expression levels of key enzymes linked to isoprenoids production in MVA pathway had been diminished after Simvastatin treatment (Fig. 7). Decreased prenylation of Rab7 have been reported to impair

**Fig. 9** Inhibition of Rab7 recruitment to lysosome by CID1067700 aggravated defect of late autophagic flux in NSC34-hSOD1<sup>G93A</sup> cells. A–C Simvastatin-treated NSC34-hSOD1<sup>G93A</sup> cells were incubated with or without GGPP (10 µM) for 24 h, and were treated with GGPP (10 µM) for 24 h combined with CID1067700 (40 µM) for 2 h before cell harvesting. CID1067700, a late endosome GTPase Rab7 receptor antagonist. Nuclei were stained with DAPI (blue). A Immunofluorescence labeling of Rab7 (red) and LAMP2 (green) in per cell group. B Immunofluorescence labeling of LC3 (red) and P62 (green) in per cell group. C Immunofluorescence labeling of LC3 (red) and LAMP2 (green) in per cell group. (Scale bars, 10 µm). D Schematic view of the potential mechanisms by which simvastatin inhibited Rab7-driven membrane fusion of autophagosomes with lysosomes, leading to aggravated impairment of late autophagic flux and accelerated neuron death.
autophagy. Our current study demonstrated that anchor of Rab7 to lysosome has been effectively rescued with supplementation of FPP or GGPP in Simvastatin-treated NSC34-hSOD1G93A cells (Figs. 8 and S1). Consistent with the fact that lack of FPP or GGPP associated with reduced autophagic flux30, supplement of FPP or GGPP reversed largely inhibitory effect of statin on autophagosomes fusion with lysosomes and further promoted degradation of SOD1 (Figs. 8 and S1). It is known that activity of Rab7 binding to lysosomal membrane is specifically blocked by CID106770052,53. We also observed that addition of GGPP was still unable to rescue late stage of autophagic flux defects induced by simvastatin under the condition of CID1067700 (Figs. 9 and S2). Overall, we proposed one possible mechanism in NSC34-hSOD1G93A cells wherein statins, inhibiting synthesis of isoprenoids and decreasing protein prenylation, could block Rab7 location to lysosome and repress autophagic flux. Notably, a widely accepted view is the pleiotropic effects of statin associated with lack of prenylation but independent of reduction of cholesterol54,60. Recent study reported that free cholesterol was unaltered in atorvastatin-treated cells59,60. Recent study reported that lack of FPP or GGPP associated with lack of prenylation but independent of reduction of cholesterol59,60. Recent study reported that free cholesterol was unaltered in atorvastatin-treated neurons59,60. Similar to previous studies, our results showed that simvastatin unaltered the level of free cholesterol in NSC34-hSOD1G93A cells (Fig. S1F).

Our results exposed that simvastatin inhibited isoprenoids synthesis in the MVA pathway, which further impeded prenylation of Rab7 accompanied by inhibitory localization of Rab7 to lysosomal membrane as well as deteriorated blockage of autophagic flux at late stage. In this case, simvastatin ultimately resulted in massive neuronal death and earlier onset of the disease phenotype in SOD1G93A mice. The present study together with our previous findings suggested the potential risk of statin-induced neuronal death. Therefore, a caution needs to be payed for further clinic application of statins in ALS.

Acknowledgements
We thank Weisong Duan, Dongxia Wu, and Zhongyao Li for suggestions and technical assistance.

Author contributions
Y.L. and RL. conceptualized and designed the experiments. LB, Y.W, J.H, SL, Y.W. QL, and J.Y performed all the experiments. Y.L, RL, and LB analyzed and interpreted the data. RL and LB wrote the manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (NSFC) 81871001 and the Key Project of Technical Health Research and Achievement Transformation of Hebei Provincial Department of Health zh20188004 and Training Project for Professional leaders of Hebei Provincial Department of Finance.

Data availability
The data generated and analyzed in this study are available from the corresponding authors upon request.

Ethics statement
All animals were kept in a pathogen-free environment with chow food and clean water. All experiments were approved by the Research Ethics Committee of the Second Hospital of Hebei Medical University (Shijiazhuang, Hebei, P.R. China, Approval No. 2020P023). All applicable institutional and government regulations regarding the use of animals were followed.

Conflict of interest
The authors declare no competing interests.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-03669-w.

Received: 11 September 2020 Accepted: 25 March 2021
Published online: 12 April 2021

References
1. Brown, R. H. & Al-Chalabi, A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 377, 162–172 (2017).
2. Turner, M. R. et al. Genetic screening in sporadic ALS and FTD. J. Neurol. Neurosurg. Psychiatry 88, 1042–1044 (2017).
3. Nguyen, D., Thombre, R. & Wang, J. Autophagy as a common pathway in amyotrophic lateral sclerosis. Neurosci. Lett. 697, 34–48 (2019).
4. Ferraiuolo, L., Kirby, J., Grierson, A. J., Sendtner, M. & Shaw, P. J. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neuro. 7, 616–630 (2011).
5. Butti, Z. & Patten, S. A. RNA dysregulation in amyotrophic lateral sclerosis. Front. Genet. 9, 712 (2018).
6. Taylor, J. P., Brown, R. H. & Cleveland, D. W. Decoding ALS: from genes to mechanism. Nature 539, 197–206 (2016).
7. Li, W. et al. Selective autophagy of intracellular organelles: recent research advances. Theranostics 11, 222–256 (2021).
8. Dikic, I. & Elazar, Z. Mechanism and medical implications of mammalian autophagy. Nat. Rev. Mol. Cell Biol. 19, 349–364 (2018).
9. Stamatikou, E. et al. Mendelian neurodegenerative disease genes involved in autophagy. Cell Disc. 6, 24 (2020).
10. Guerra, F. & Bucci, C. Multiple roles of the small GTPase Rab7. Cells 5, 34–62 (2016).
11. Stroope, C. This is the end: regulation of Rab7 nucleotide binding in endolysosomal trafficking and autophagy. Front. Cell Dev. Biol. 6, 120 (2018).
12. Fassio, A. et al. Emerging role of the autophagy/lysosomal degradative pathway in neurodevelopmental disorders with epilepsy. Front. Cell Neurosci. 14, 39 (2020).
13. Giovedi, S., Ravanelli, M. M., Patri, B., Bettegazzi, B. & Guarnieri, F. C. Dysfunctional autophagy and endolysosomal system in neurodegenerative diseases: relevance and therapeutic options. Front. Cell Neurosci. 14, 620116 (2020).
14. Kuang, H. et al. Exploring the bi-directional relationship between autophagy and Alzheimer's. CNS Neurosci. Ther. 26, 155–166 (2020).
15. Cipolat Mis, M. S., Bajovic, S., Frattini, E., Di, F. A. & Corti, S. Autophagy in motor neuron disease: key pathogenetic mechanisms and therapeutic targets. Mol. Cell Neurosci. 72, 84–90 (2016).
16. Wernberk, K., Rossman, K. L. & Der, C. J. The Ras superfamily at a glance. J. Cell. Sci. 118, 843–846 (2005).
17. Miettinen, T. P. & Björklund, M. Mevalonate pathway regulates cell size homeostasis and proteostasis through autophagy. Cell. Sci. 8, 2610–2620 (2015).
18. Gruenbacher, G. & Thurnheer, M. Mevalonate metabolism in cancer stemness and trained immunity. Front. Oncol. 8, 394 (2018).
19. Tricario, P. M., Crovella, S. & Celis, F. Mevalonate pathway blockade, mitochondrial dysfunction and autophagy: a possible link. Int. J. Mol. Sci. 16, 16067–16084 (2015).
20. Tricario, P. M., Romeo, A., Gratton, R., Crovella, S. & Celis, F. Lack of prenylated proteins, autophagy impairment and apoptosis in SH-SYSY neuronal cell model of mevalonate kinase deficiency. Cell. Physiol. Biochem. 41, 1649–1660 (2017).
21. Kazi, D. S., Penko, J. M. & Bibbins-Domingo, K. Statins for primary prevention of cardiovascular disease: review of evidence and recommendations for clinical practice. *Med. Clin. North Am.* 101, 689–699 (2017).

22. Yang, Z. et al. Association of blood lipids, atherosclerosis and statin use with dementia and cognitive impairment after stroke: a systematic review and meta-analysis. *Aging Cell* Rev. 57, 100962 (2020).

23. Chung, J. W. et al. Intensive statin treatment in acute ischaemic stroke patients with intracranial atherosclerosis: a high-resolution magnetic resonance imaging study (STAVIN-MRI Study). *J. Neural. Neurosurg. Psychiatry* 91, 204–211 (2020).

24. Zhang, Q., Dong, J. & Yu, Z. Pleiotropic use of statins as non-lipid-lowering drugs. *Int. J. Biol. Sci.* 16, 2704–2711 (2020).

25. Chan, D. et al. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. *Lancet Neurol.* 16, 591–600 (2017).

26. Saeedi Saravi, S. S., Saeedi Saravi, S. S., Arezou, A. & Dehpour, A. R. The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration. *Metab. Brain Dis.* 32, 949–965 (2017).

27. Mulchandani, R., Lyngdoh, T. & Kakkar, A. K. Statin use and safety concerns: an overview of the past, present and the future. *Expert Opin. Drug Saf.* 19, 1011–1024 (2020).

28. Meurer, T. L. & Cohen, S. M. Drug-induced liver injury from statins. *Clin. Liver Dis.* 24, 107–119 (2020).

29. Wang, Y. F. et al. Simvastatin enhances muscle regeneration through autophagic defect-mediated inflammation and mTOR activation in G93ASOD1 mice. *Mol. Neurobiol.* 58, 1593–1609 (2021).

30. Qi, W. J. et al. Simvastatin aggravates impaired autophagic flux in NSC34-hSOD1G93A cells through inhibition of geranylgeranyl pyrophosphate synthesis. *Neuroscience* 409, 130–141 (2019).

31. Gurney, M. E. et al. Motor neuron degeneration in mice that express a human Cu2Zn superoxide dismutase mutation. *Science* 264, 1772–1775 (1994).

32. Weydt, P., Hongso, Y., Kliot, M. & Moller, T. Assessing disease onset and progression in the SOD1 mouse model of ALS. *Neuroreport* 14, 1051–1054 (2003).

33. Vercell, A. et al. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. *Neurobiol. Dis.* 31, 395–405 (2008).

34. Klosnky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy* 12, 1–222 (2016).

35. Lucoq, J. M. & Hacker, C. Cutting a flux in NSC34-CTF25 of TDP-43 depends on the proteasome. *Autophagy* 9, 1443–1448 (2013).

36. Zhan, L. et al. Autophagosome maturation mediated by Rab7 contributes to neuroprotection of hypoxic preconditioning against global cerebral ischemia in rats. *Cell Death Dis.* 8, e2949 (2017).

37. Cashman, N. R. et al. Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. *Dev. Dyn.* 194, 209–221 (1992).

38. Liu, Y. et al. A new cellular model of pathological TDP-43: the neurotoxicity of stably expressed CTF25 of TDP-43 depends on the proteasome. *Neuroscience* 281, 88–98 (2014).

39. Salehi, M., Nikkhah, M., Ghasemi, A. & Arab, S. S. Mitochondrial membrane disruption by aggregation products of ALS-causing superoxide dismutase-1 mutants. *Int. J. Biol. Macromol.* 75, 290–297 (2015).

40. Paré, B. et al. Misfolded SOD1 pathology in sporadic amyotrophic lateral sclerosis. *Sci. Rep.* 8, 14223–14237 (2018).

41. Wang, J. et al. Copper-binding-site-null SOD1 causes ALS in transgenic mice: aggregates of non-native SOD1 delineate a common feature. *Hum. Mol. Genet.* 12, 2753–2764 (2003).

42. Bruijn, L. I. et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. *Science* 281, 1851–1856 (1998).

43. Reddy, R. L. & Dokholyan, N. V. The complex molecular biology of amyotrophic lateral sclerosis (ALS). *Prog. Mol. Biol. Transl. Sci.* 107, 215–262 (2012).

44. Proctor, E. A. et al. Nonnative SOD1 trimer is toxic to motor neurons in a model of amyotrophic lateral sclerosis. *Proc. Natl Acad. Sci. USA* 113, 614–619 (2016).

45. Foster, A. D. & Rea, S. L. The role of sequestosome 1/p62 protein in amyotrophic lateral sclerosis and frontotemporal dementia pathogenesis. *Neural Regen. Res.* 15, 2186–2194 (2020).

46. Lippai, M. & Low, P. The role of the selective adaptor p62 and ubiquitin-like proteins in autophagy. *Biomed. Res. Int.* 2014, 832704 (2014).

47. Yoshi, S. R. & Noboru, M. Monitoring and measuring autophagy. *Int. J. Mol. Sci.* 18, 1865 (2017).

48. Kuchitsu, Y. & Fukuda, M. Revisiting Rab7 functions in mammalian autophagy: Rab7 knockout studies. *Cells* 7, 215–226 (2018).

49. Jäger, S. et al. Role for Rab7 in maturation of late autophagic vacuoles. *J. Cell Sci.* 117, 4837–4848 (2004).

50. Kou, X. et al. Vorinostat and simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating rab7 ptenylation. *Eur. J. Pharmacol.* 85, B13–B24 (2020).

51. Rajani, R. et al. N6-isopentenyladenosine dual targeting of AMPK and Rab7 ptenylation inhibits melanoma growth through the impairment of autophagic flux. *Cell Death Differ.* 25, 353–367 (2018).

52. Hong, L. et al. A Pan-GTPase inhibitor as a molecular probe. *PLoS ONE* 10, e0134317 (2015).

53. Qin, Y. et al. CID1067700, a late endosome GTPase Rab7 receptor antagonist, attenuates brain atrophy, improves neurologic deficits and inhibits reactive astroglisis in rat ischemic stroke. *Acta Pharmacol. Sin.* 40, 724–736 (2019).

54. Fracassi, A., Marangoni, M., Rossio, P., Pallottini, V. & Segatto, M. Statins and the brain: more than lipid lowering agents? *Curr. Neuropharmacol.* 17, 59–83 (2019).

55. Sinton, C. R. The pharmacology of statins. *Pharmacol. Res.* 88, 3–11 (2014).

56. Ahmed, M. et al. Pleiotropic effects of statins: a focus on cancer. *Biochem. Biophys. Acta Mol. Basis Dis.* 1866, 165968 (2020).

57. Luddolph, A. C. et al. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/NINDS: report on the 142nd ENMC international workshop. *Amyotroph. Lateral Scler.* 8, 217–223 (2007).

58. Barr, F. A. Rab GTPases and membrane identity: causal or inconsequential? *J. Cell Biol.* 202, 191–199 (2013).

59. Woschek, M., Kreip, N., Jurida, K., Marj, I. & Relja, B. Simvastatin reduces cancerogenic potential of renal cancer cells via geranylgeranyl pyrophosphate and mevalonate pathway. *Nutr. Cancer* 68, 420–427 (2016).

60. Oesterle, A. & Liao, J. K. The pleiotropic effects of statins-from coronary artery disease and stroke to atrial fibrillation and ventricular tachyarrhythmia. *Curr. Vasc. Pharmacol.* 17, 222–232 (2019).

61. van der Kant, R. et al. Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-β in iPSC-derived Alzheimer’s disease neurons. *Cell Stem Cell* 24, 363–375.e9 (2019).

62. Ohm, T. G. et al. Cholesterol and tau protein-findings in Alzheimer’s and frontotemporal dementia. *Pharmacopsychiatry* 36, S120–S126 (2003).